Diabetes and bone health: The relationship between diabetes and osteoporosis-associated fractures

Diabetes/Metabolism Research and Reviews

Volumn 27, Issue 5, 2011, Pages 430-435

  Kurra, Salila ^a   Siris, Ethel ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Bone; Diabetes; Osteoporosis

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; GLIBENCLAMIDE; METFORMIN; OSTEOCALCIN; PIOGLITAZONE; ROSIGLITAZONE; THIAZOLIDINE DERIVATIVE; TROGLITAZONE;

ARM FRACTURE; BONE DENSITY; BONE MASS; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE ASSOCIATION; DRUG EFFICACY; FOOT FRACTURE; FRACTURE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RIB FRACTURE; RISK BENEFIT ANALYSIS; SIDE EFFECT; VERTEBRA FRACTURE;

ACCIDENTAL FALLS; BONE AND BONES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FRACTURES, BONE; HUMANS; OBESITY; OSTEOPOROSIS; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 79960154986     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.1197     Document Type: Review

References (46)

1. Osteoporosis Prevention, Diagnosis and Therapy. NIH Consensus Statement 2000; March 27-29; 17: 1-36.
2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 2006; 17: 1726-1733.
3. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053.
4. Yki-Jarvinen H. Drug therapy: thiazolidinediones. N Engl J Med 2004; 351: 1106-1118.
5. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int 2007; 18: 427-444.
6. Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 2005; 28: 2850-2855.
7. Schwartz AV, Sellmeyer DE, Ensrud KE, et al.; Study of Osteoporotic Features Research Group. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 2001; 86: 32-38.
8. Nicodemus KK, Folsom AR; Iowa Women's Health Study. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001; 24: 1192-1197.
9. Ahmed LA, Joakimsen RM, Berntsen GK, Fonnebo V, Schirmer H. Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study. Osteoporos Int 2006; 17: 495-500.
10. Bonds DE, Larson JC, Schwartz AV, et al. Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. J Clin Endocrinol Metab 2006; 91: 3404-3410.
11. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountain Eye Study. Diabetes and risk of fracture: the Blue Mountain Eye Study. Diabetes Care 2001; 24: 1198-1203.
12. Schwartz AV, Hillier TA, Sellmeyer DE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care 2002; 25: 1749-1754.
13. Verhaeghe J, Suiker AM, Einhorn TA, et al. Brittle bones in the spontaneously diabetic female rats cannot be predicted by bone mineral measurements: studies in diabetic and ovariectomized rats. J Bone Miner Res 1994; 9: 1657-1667.
14. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int 2006; 17: 1514-1523.
15. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab 2008; 93: 1143-1152.
16. Katayama Y, Akatsu T, Yamamoto M, Kugai N, Nagata N. Role of nonenzymatic glycosylation of type I collagen in diabetic osteopenia. J Bone Miner Res 1996; 11: 931-937.
17. Zhou Z, Immel D, Xi CX, et al. Regulation of osteoclast function and bone mass by RAGE. J Exp Med 2006; 203: 1067-1080.
18. Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab 2008; 26: 93-100.
19. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 2008; 93: 1013-1019.
20. Inaba M, Terada M, Koyama H, et al. Influence of high glucose on 1, 25-dihydroxyvitamin D3-induced effect on human osteoblast-like MG-63 cells. J Bone Miner Res 1995; 10: 1050-1056.
21. Kanazawa I, Yamaguchi T, Yamamoto M, et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 2009; 94: 45-49.
22. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes 1995; 44: 775-782.
23. Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract 1994; 23: 43-54.
24. Pittas AG, Dawson-Hughes B, Li T, et al. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006; 29: 650-656.
25. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471.
26. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
27. Kahn CR, Chen L, Cohen SE. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 2000; 106: 1305-1307.
28. Beresford JN. Osteogenic stem cells and the stromal system of bone and marrow. Clin Orthop Relat Res 1989; 240: 270-280.
29. Pittenger MF, Mackay AM, Becke SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284: 143-147.
30. Okuno A, Tamemoto H, Tobe K, et al. Troglitazone increases the number of small adipocytes without the change in white adipose tissue in obese Zucker rats. J Clin Invest 1998; 101: 1354-1361.
31. Rzonca SO, Suva LJ, Gaddy D, Montague DC, Lecka-Czernik B. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004; 145: 401-406.
32. Akune T, Ohba S, Kamekura S, et al. PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004; 113: 846-855.
33. Pei L, Tontonoz P. Fat's loss is bone's gain. J Clin Invest 2004; 113: 805-806.
34. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al. Activation of peroxisome proliferator-activated receptor γ (PPAR γ) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007; 148: 903-911.
35. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
36. Kahn SE, Zinman B, Lachin JM, et al.; Diabetes Outcome Progression Trial (ADOPT) Study Group. Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008; 31: 845-851.
37. Takeda Pharmaceutical Company. Observation of an Increased Incidence of Fractures in Female Patients Who Received Long-term Treatment with ACTOS (Pioglitazone HCl) Tablets for Type 2 Diabetes Mellitus (Letter to Health Care Providers). Takeda Pharmaceutical Company: Osaka, Japan, 2007.
38. Schwartz AV, Sellmeyer DE, Vittinghoff E, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006; 91: 3349-3354.
39. Yaturu S, Bryant B, Jain SK. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 2007; 30: 1574-1576.
40. Bilik D, McEwen LN, Brown MB, et al. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. J Clin Endocrinol Metab 2010; 95: 4560-4565.
41. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Inter Med 2008; 168: 820-825.
42. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovarian syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab 2008; 93: 1696-1701.
43. Grey A, Bolland M, Gamble G, et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, control trial. J Clin Endocrinol Metab 2007; 92: 1305-1310.
44. U.S. Preventive Services Task Force. Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med 2002; 137: 526-528.
45. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation: Washington, D.C., 2010.
46. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039.